Menu
Login

Report Library

All Reports

Post-AASLD US KOL Interview

December 16, 2014

Following our live coverage of AASLD, we interviewed an US KOL to expand on how the data events and discussions at the meeting will impact the current treatment practices in Hepatitis C. Additionally, we discussed drugs in development for NASH and Hepatitis B and any relevant data from the meeting in these indications.

Key Highlights
  • Phase II C-SWIFT data was not a complete failure as it shows drug combinations will likely get to shorter durations, but this is not a concern of physicians – mostly payers (MRK).
  • No more than a quarter of treatment-naïve patients with GT1 HCV have viral load over 6M. These patients will be treated with 12 weeks Harvoni, versus 8 week (GILD).
  • Reimbursement for Harvoni has been mostly limited to patients with >F2 fibrosis (GILD).
  • ABBV 3D will need to compete on price once approved, and it may have the advantage to Harvoni in patients who are treatment experienced cirrhotics or have end-stage renal disease (ESRD) (ABBV).
  • The BMY Trio doesn’t have much competitive advantage to ABBV 3D and will also have to compete on price with Harvoni (BMY).
  • Clinical data from Achillion is still expected to determine how their nuc compares to sofosbuvir. Data from the “proxy” study was positive but not telling (ACHN).
  • NASH is an area of high unmet need, so INT-747 may be approvable despite moderate efficacy given safety is okay in a larger Phase III study (ICPT).
  • Hepatitis B drugs will likely need to be used in a cocktail to achieve significant reduction in viral load (ARWR, ALNY, TKMR, GILD).


For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
Indications Covered: Hepatic Fibrosis
Hepatitis B (HBV) Treatment (Antiviral)
Hepatitis B Prevention (Vaccines, Antiviral)
Hepatitis C (HCV) (Antiviral)
Hepatitis C Prevention (Vaccines, Antiviral)
Non-Alcoholic Steatohepatitis (NASH)

 Additional Resources: